Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts give Rani Therapeutics a “Moderate Buy” consensus rating: Four analysts recommend buying the stock, one rates it a strong buy, and one recommends selling. The average 12-month price target is $8.75.
• Rani shares opened at $0.78, near their 50-day and 200-day moving averages, with a market capitalization of approximately $108.4 million. The stock has traded between $0.45 and $3.87 over the past year.
• The company reported quarterly revenue of $1.71 million and an adjusted loss of $0.04 per share, beating analyst estimates. CEO Talat Imran also purchased 35,000 shares, while insiders and institutions own 26.73% and 30.19% of the stock, respectively.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.75.

Several analysts have recently weighed in on RANI shares. Weiss Ratings lowered Rani Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating on shares of Rani Therapeutics in a report on Friday, August 21st. Finally, Chardan Capital upgraded shares of Rani Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 26th.

Insider Activity

In other Rani Therapeutics news, CEO Talat Imran bought 35,000 shares of the company's stock in a transaction that occurred on Friday, July 17th. The shares were acquired at an average cost of $0.72 per share, for a total transaction of $25,200.00. Following the acquisition, the chief executive officer directly owned 469,736 shares of the company's stock, valued at $338,209.92. This trade represents a 8.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 26.73% of the stock is owned by corporate insiders.

Institutional Trading of Rani Therapeutics

Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. bought a new position in shares of Rani Therapeutics in the second quarter valued at $5,703,000. Squarepoint Ops LLC boosted its stake in shares of Rani Therapeutics by 155.5% during the 2nd quarter. Squarepoint Ops LLC now owns 41,902 shares of the company's stock worth $32,000 after acquiring an additional 25,501 shares in the last quarter. Kestra Private Wealth Services LLC grew its holdings in shares of Rani Therapeutics by 4.1% in the 1st quarter. Kestra Private Wealth Services LLC now owns 265,159 shares of the company's stock worth $195,000 after acquiring an additional 10,347 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Rani Therapeutics during the fourth quarter worth $40,000. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Trading Down 1.5%

Shares of NASDAQ:RANI opened at $0.78 on Wednesday. The company has a 50 day moving average of $0.82 and a 200-day moving average of $0.89. The firm has a market cap of $108.44 million, a P/E ratio of -2.88 and a beta of 0.69. Rani Therapeutics has a twelve month low of $0.45 and a twelve month high of $3.87.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $1.71 million for the quarter, compared to the consensus estimate of $0.93 million. Equities research analysts forecast that Rani Therapeutics will post -0.17 EPS for the current year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologic medicines that are traditionally administered by injection or infusion. The company's platform is designed to use a swallowable, robotic capsule to transport medicine through the stomach and release it in the small intestine, where the drug can be delivered into the body.

Rani's technology, known as the RaniPill capsule, is intended to address challenges associated with injectable therapies, including the need for administration by a healthcare professional and patient reluctance toward injections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.